Elicera Therapeutics (ELIC) Investor Update summary

Clinical program updates

• Karma-study's first CAR-T patient with B-cell lymphoma achieved complete response after one month, despite receiving only one-tenth of the planned maximum dose.

• Full recruitment achieved for the Advin-study (oncological virus in neuroendocrine tumors); final results expected by summer, with strategic decisions on next steps to follow.

• Karma-study will report data at ISCT conference in May and after each cohort; faster patient recruitment expected compared to Advin-study.

• ELC401 (CAR-T for glioblastoma) and ELC201 (oncological virus) remain preclinical, with clinical entry dependent on securing soft funding or partnerships.

• Orphan drug designation granted for ELC-100 in pancreatic neuroendocrine tumors, providing regulatory and financial advantages.

ITANK platform and preclinical data

• ITANK platform arms CAR-T therapies with a bacterial protein to trigger broader immune responses and overcome solid tumor challenges.

• Preclinical data show ITANK-armed CAR-T therapies lead to longer survival and reduced tumor growth in mice, with some cases of complete tumor eradication and immune memory.

• No additional toxicity observed preclinically with ITANK; first Karma-study patient had only mild side effects.

• ITANK platform is being out-licensed to academic partners in Spain, USA, and China, with potential for future licensing revenues.

Financial and strategic outlook

• Ongoing options program will secure SEK 22 million, extending cash runway into the second half of 2027 and covering key data readouts for Karma-study.

• Multiple clinical data releases expected in 2025, including from Karma and Advin studies.

• Strategic focus on securing non-dilutive funding or partnerships for advancing preclinical programs into clinical trials.

• Potential for ITANK licensing deals to further strengthen financial position.